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Abstract Preformed amyloid ¢brils accelerate conformational
changes of amyloid precursor proteins and result in rapid ex-
tension of amyloid ¢brils in vitro. We injected various kinds of
amyloid ¢brils into mice with amyloidogenic apoAII gene
(Apoa2C ). The most severe amyloid depositions were detected
in the tissues of mice injected with mouse AApoAII(C) amyloid
¢brils. Mild amyloid depositions were also detected in the tis-
sues of mice that were injected with other types of ¢brils, in-
cluding synthetic peptides and recombinant proteins. However,
no amyloid depositions were found in mice that were injected
with non-amyloid ¢bril proteins. These results demonstrated
that a common structure of amyloid ¢brils could serve as a
seed for amyloid ¢bril formation in vivo.
' 2004 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Amyloidosis refers to a group of protein folding diseases,
including currently prominent diseases such as Alzheimer’s,
prion diseases, and type 2 diabetes. Amyloidosis is character-
ized by the deposition of ¢ne and insoluble ¢brils from the
polymerization of soluble proteins which undergo marked
conformational changes. Amyloid ¢brils have a high degree
of L-sheet structure. To date, more than 30 amyloid ¢bril
proteins have been identi¢ed [1]. Prion diseases are highly
infectious and transmissible. The current widely accepted
prion protein hypothesis suggests that the amyloidogenic
and protease-resistant form (PrPsc) of the protein propagates
itself by inducing a conformational change in the normal
prion protein (PrPc). Nucleation-dependent polymerization
or seeding is postulated to explain the propagation of prion
diseases [2,3] and pathogenesis of non-prion amyloidosis [4].
However, the molecular nature of the template for ¢bril for-
mation in vivo is still open for debate.
ApoA-II is the second most abundant apolipoprotein in
plasma high-density lipoprotein (HDL) after apoA-I. ApoA-
II amyloidosis has been found in patients with hereditary
renal amyloidosis [5]. In mice, apoA-II is a precursor of amy-
loid ¢brils (AApoAII) in senile amyloidosis [6,7]. Senescence-
accelerated prone (SAMP1) mice having a variant C-type
apoA-II (APOAIIC, Gln5 and Ala38) spontaneously exhibit
a high incidence of AApoAII amyloidosis with aging [8]. Se-
nescence-accelerated resistant (SAMR1) mice with wild-type B
apoA-II (APOAIIB, Pro5, and Val38) show few, if any, signs
of AApoAII amyloidosis. R1.P1-Apoa2c mice are a congenic
strain with the amyloidogenic allele of the apoA-II gene from
the SAMP1 strain on the genetic background of the SAMR1
strain [9]. These mice spontaneously exhibit a high incidence
of amyloidosis and severe amyloid deposition with aging [10].
In previous studies we demonstrated that intravenous injec-
tion of AApoAII amyloid ¢brils dramatically accelerated the
progress of amyloidosis in the R1.P1-Apoa2c strain suggesting
the transmission of amyloid ¢brils via the gastrointestinal
tract from mice with severe amyloid deposition to those with-
out [11,12]. Prion-like transmission has also been revealed in a
study of in£ammation-associated experimental (AA) amyloi-
dosis [13]. Thus it has been shown that amyloid diseases may
be transmissible under certain conditions.
All amyloid ¢brils share some common features, including a
high degree of L-sheet structure in a classical ‘cross-L’ pattern,
a ¢brillar morphology seen under electron microscopy, and
the ability to bind and alter the spectroscopic properties of
the heteroaromatic dyes Congo red and thio£avine T. It has
been suggested that the cross-L conformation is dominated by
main-chain interactions that are common to di¡erent polypep-
tides [14]. AA amyloidosis has been induced by transthyretine
amyloid ¢brils (ATTR) [15], synthetic amyloid-like ¢brils [16],
and modi¢ed silk [17] administered intravenously. The syner-
gistic ¢brillization of Tau and alpha-synuclein has been dem-
onstrated [18] and the appearance of prions is enhanced by
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heterologous prion aggregates in yeast [19]. Thus the contri-
bution of interactions or cross-talk between various amyloid
¢brils and amyloid proteins to the pathogenesis of amyloido-
sis has been speculated.
Here we report the results of induction of AApoAII amy-
loidosis by various amyloid ¢brils extracted from tissues or
formed from recombinant protein or synthetic peptides. We
found that all of these amyloid proteins accelerated AApoAII
amyloidosis. Our results demonstrate that the existence of a
generic structure present in many amyloid ¢brils might serve
as a seed for amyloidogenesis.
2. Materials and methods
2.1. Animals
Amyloidogenic R1.P1-Apoa2c and SAMR1 mice were raised in the
Division of Laboratory Animal Research, Research Center for Hu-
man and Environmental Sciences, Shinshu University, under standard
conditions at 24Q 2‡C with a light-controlled regimen (12 h light/dark
cycle). A commercial diet (MF; Oriental Yeast, Tokyo, Japan) and
tap water were available ad libitum. All experiments were performed
with the consent of the Animal Care and Use Committee of Shinshu
University School of Medicine.
2.2. Isolation of amyloid ¢brils from tissues
Human AA ¢brils (hAA) were obtained from an autopsied thyroid
of a female patient (49 years old) with rheumatoid arthritis. Human
TTR ¢brils (hATTR) were obtained from an autopsied heart of a
male familial amyloidotic polyneuropathy (FAP) patient (86 years
old) with a Val30Met TTR mutation. Two kinds of human AL ¢brils
(hAL) were obtained from autopsied spleens of two female patients
(85 and 68 years old) with primary amyloidosis. L2-microglobulin
¢brils (AL2M) were obtained from autopsied tendon sheaths of a
patient on long-term dialysis. Mouse AApoAII(C) and AApoAII(A)
¢brils were isolated from the liver of an R1.P1-Apoa2c mouse and the
intestine of a BDF1 mouse, respectively. Mouse AA ¢brils (mAA)
were isolated from the liver of a C57BL/6 mouse with severe sponta-
neous AA amyloidosis.
The various amyloid ¢brils were isolated as water suspension frac-
tions and further puri¢ed by ultracentrifugation as described previ-
ously [12].
2.3. Amyloid ¢brils of recombinant proteins and synthetic peptide
K-Synuclein cDNA was cloned from human brain tissue, expressed
in Escherichia coli, and the recombinant protein was puri¢ed. Puri¢ed
K-synuclein was incubated in bu¡er (25 mM Tris^HCl, 1 M NaCl, pH
7.5) for 17 days at 37‡C to make amyloid ¢brils (AK-synuclein).
GroES was expressed in E. coli and puri¢ed. Amyloid ¢brils were
formed from GroES incubated in bu¡er (25 mM Tris^HCl, 1.6 M
guanidine-hydrochloride, pH 7.5) for 5 days at 37‡C (AGroES). Amy-
loid ¢brils were formed from lysozyme (hen egg white lysozyme,
Wako Pure Chemical Industries, Ltd., Osaka, Japan) incubated in
HCl (pH 2.0) for 7 days at 65‡C (ALysozyme). AL140 (Bachem
AG, Bubendorf, Switzerland) ¢brils were formed after incubation in
reaction mixture (50 WM AL140, 50 mM phosphate bu¡er, pH 7.5,
and 100 mM NaCl) for 24 h at 37‡C.
2.4. Induction and detection of amyloidosis
2-month-old female R1.P1-Apoa2c and SAMR1 mice were injected
intravenously with 0.1 mg of various sonicated amyloid ¢brils as
described previously [12]. Control mice were injected with distilled
water (DW), human albumin (Sigma-Aldrich, Tokyo, Japan), or hu-
man transthyretin (Wako Pure Chemical Industries). Mice were killed
by cardiac puncture under diethyl ether anesthesia at 3, 6, and 12
months after injection. One half of each organ was stored frozen until
amyloid ¢bril isolation. The remaining halves were ¢xed in 10% bu¡-
ered formalin, embedded in para⁄n, and cut into 4-Wm serial sections.
The intensity of amyloid deposition was determined using the amy-
loid index (AI) as a parameter. AI was the average of grades 0^4 in
seven organs (liver, spleen, skin, heart, stomach, small intestine, and
tongue) stained with Congo red after immunohistochemical con¢rma-
tion of the AApoAII deposition [20].
Proteins (5 Wg) in the amyloid fraction [12] were separated by 16.5%
sodium dodecyl sulfate^polyacrylamide gel electrophoresis (SDS^
PAGE) with a Tris^tricine bu¡er system and electrotransferred to a
polyvinylidene di£uoride (PVDF) membrane (Bio-Rad; Hercules, CA,
USA) and immunodetected by anti-AApoAII antiserum (1:5000 dilu-
tion).
2.5. Electron microscopy
10 Wl of amyloid fractions (0.4 mg/ml) and 10 Wl of 2% phospho-
tungstic acid (pH 7.0) were mixed. Half of a carbon-coated plastic
grid (Ouken, Tokyo, Japan) was immersed in this mixture for 1 s. The
negatively stained samples were observed with a JEOL 1200 EX elec-
tron microscope (JEOL, Tokyo, Japan) operated at 80 kV.
2.6. Statistical analysis
The AI of AApoAII deposition in the di¡erent groups was com-
pared with results of the Mann^Whitney U-test.
3. Results
3.1. Transmission electron microscopy of amyloid ¢brils
We observed various types of negatively stained amyloid
¢brils using transmission electron microscopy. All of the
samples exhibited amyloid-characteristic unbranched ¢bril im-
ages (Fig. 1). The diameter and length of the various ¢brils
were as follows: AApoAII(C), 9.02Q 1.25 and 439.28Q 43.38
nm; AApoAII(A), 9.05Q 1.28 and 87.58Q 10.39 nm; mAA,
10.03Q 1.30 and 90.12Q 9.77 nm; hAA, 13.01Q 1.17 and
380.25Q 36.59 nm, hATTR, 12.04Q 1.08 and 100.06Q 20.01
nm; hAL-1, 13.01Q 1.95 and 150.43Q 18.45 nm; hAL-2,
13.02Q 1.34 and 145.22Q 16.23 nm; AL2M, 10.01Q 1.56 and
305.21Q 19.56 nm; AK-synuclein, 11.01 Q 1.07 and 401.20Q
21.04 nm; AGroES, 12.05 Q 1.32 and 108.42Q 13.72 nm;
ALysozyme, 10.03Q 1.20 and 441.28Q 24.60 nm; and
AL140, 9.02Q 1.23 and 442.06Q 18.75 nm, respectively.
3.2. Induction of mouse AApoAII amyloidosis by mouse
amyloid ¢brils
3 months after treatment, AApoAII deposition was ob-
served in all AApoAII(C)-injected mice (Fig. 2). At 6 months
severe amyloid deposition was seen throughout the entire
body with the exception of bone and brain parenchyma. AA-
poAII depositions were also induced by mAA and mouse
AApoAII(A) amyloid ¢brils. The intensity of amyloid depo-
sitions was signi¢cantly lower than that seen in mice 3 and
6 months after AApoAII(C) injection (P6 0.05 by Mann^
Whitney U-test) (Fig. 2). mAA deposits were not detected
by immunohistochemistry (data not shown).
3.3. Induction of mouse AApoAII amyloidosis by human
amyloid ¢brils
We detected slight AApoAII deposition in the interstitium of
the myocardium, the lamina propria of the tongue (Fig. 3a, A
and B), the lamina propria and submucosa of the small intes-
tine, and the glandular portion and squamous glandular junc-
tion of the stomach in all hAA amyloid ¢bril-injected mice at
3 months after injection. At 6 months after injection there was
severe AApoAII deposition in the tongue (Fig. 3a, D and E),
and moderate AApoAII deposition in the liver, spleen, heart,
skin, stomach and small intestine. AApoAII deposits were also
induced by hATTR, AL, and AL2M ¢brils. However, the de-
gree of amyloid deposition was signi¢cantly lower than that
seen in mice at 3 and 6 months after hAA injection (P6 0.05
by Mann^Whitney U-test) (Fig. 2). Immunohistochemical
staining did not detect mAA deposits (Fig. 3a, C and F).
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Fig. 1. Transmission electron microscopy images of amyloid ¢brils. Amyloid ¢brils were negatively stained. A: AApoAII(C); B: AApoAII(A);
C: mAA; D: hAA; E: hATTR; F: hAL-1; G: hAL-2; H: hAL2M; I: AK-synuclein; J: AGroES; K: ALysozyme; L: AL140 ¢brils. The scale
bar indicates 100 nm.
Fig. 2. Comparison of the AI in various amyloid ¢brils injected into R1.P1-Apoa2c and SAMR1 mice. In R1.P1-Apoa2c mice, a signi¢cant dif-
ference in AI was found between the hAA, hATTR, hAL-1, hAL-2, hAL2M ¢bril groups, and the mouse AApoAII(C) and mouse AApoAII(A)
or mAA ¢bril groups. Non-treated R1.P1-Apoa2c mice are 5, and 8 months old. Non-treated SAMR1 mice are 5, and 14 months old.
*P6 0.05 by the Mann^Whitney U-test. **12 months after injection.
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To investigate the kinetics of amyloid ¢bril formation,
R1.P1-Apoa2c mice were injected intravenously with 0.2 mg
hAA ¢brils and euthanized at 2, 4, and 6 weeks, and 2 and
3 months after injection. ApoA-II proteins in the amyloid
¢bril fractions were then detected in the tissues. AApoAII
deposits were ¢rst detected in the lungs at 4 weeks after in-
jection. At 6 weeks after injection, AApoAII deposits ex-
tended into the tongue and stomach. At 3 months after in-
jection, AApoAII deposits were detected in the lungs,
stomach, liver, and tongue (Fig. 3b). However, we failed to
detect injected human amyloid ¢brils in the tissues (data not
shown).
3.4. Induction of AApoAII amyloidosis by recombinant and
synthetic ¢brils
At 3 months after treatment with recombinant and syn-
thetic ¢brils, slight AApoAII deposits were detected in the
tissues of the AL140-, AK-synuclein-, and AGroES-injected
mice. No amyloid deposits were detected in the tissues of
ALysozyme-injected mice. At 6 months after treatment the
amyloid deposits became more extensive. The most severe
amyloid deposits were detected in the tissues of AGroES-in-
jected mice. AApoAII deposits were detected in the tongue,
liver (Fig. 4B and E), spleen, heart, stomach, and small intes-
tine. No mAA deposits were observed (Fig. 4C and F).
To study the e¡ect of amyloid ¢bril structure on amyloid
induction, we injected DW and two kinds of non-amyloid
proteins including human albumin and hTTR proteins. We
did not observe amyloid deposition in any tissues as late as
6 months after injection (Fig. 2).
3.5. Induction of AApoAII amyloidosis in SAMR1 mice
To investigate the e¡ect of the mouse Apoa2 allele on amy-
loid induction, hATTR and synthetic AL140 ¢brils were in-
jected into SAMR1 mice which have the less amyloidogenic
Apoa2b. No amyloid deposition was observed at 3 or 12
months after injection (Fig. 2).
4. Discussion
In this study, we demonstrated the induction of mouse AA-
poAII amyloidosis from various types of amyloid ¢brils.
These results suggest that a generic conformation present in
these amyloid ¢brils may serve as a seed to accelerate con-
formational changes of amyloid proteins. Despite this promis-
cuity, the degree of induced amyloid deposition was highest
when injected amyloid ¢brils had the same sequence as the
Fig. 3. AApoAII deposition in tissues of hAA-treated R1.P1-Apoa2c
mice. a: Amyloid deposits in the papillary layer of the tongue of a
mouse at 3 and 6 months (grades 2 and 4 respectively) after hAA
injection were identi¢ed by green birefringence in Congo red-stained
sections using polarizing microscopy (A and D). AApoAII deposits
were identi¢ed by immunohistochemical staining using anti-AA-
poAII antiserum (1:5000) (B and E). mAA deposits were excluded
from amyloid deposits by immunohistochemical staining using anti-
mAA antiserum (1:3000) (C and F). Arrows show the AApoAII de-
posits in tissues. Scale bar equals 100 Wm. b: Western blot analysis
of AApoAII amyloid protein. Lane 1, lung; lane 2, small intestine;
lane 3, stomach; lane 4, liver; lane 5, tongue. The AApoAII amy-
loid protein was detected in tissues at 2, 4, 6 weeks, and 2 and
3 months after hAA injection.
Fig. 4. AApoAII deposition in tissues of an AGroES-injected
R1.P1-Apoa2c mouse. Amyloid deposits in the papillary layer of the
tongue (grade 3) and around the central vein in the liver (grade 2)
of a mouse at 6 months after AGroES injection were identi¢ed by
green birefringence in Congo red-stained sections using polarizing
microscopy (A and D). AApoAII deposits were identi¢ed (B and E)
and mAA deposits were excluded from amyloid deposits by immu-
nohistochemical staining (C and F). Arrows show the AApoAII de-
posits in tissues. Scale bar equals 100 Wm.
FEBS 28250 29-3-04 Cyaan Magenta Geel Zwart
X. Fu et al./FEBS Letters 563 (2004) 179^184182
endogenous amyloid protein. The high sequence speci¢city of
the propagation has also been revealed in prion diseases and
yeast prions [21,22]. These phenomena cause ‘species barriers’
that limit transmission. Our ¢ndings suggest that the generic
and speci¢c conformation of amyloid ¢brils may serve to
modify the transmission of non-prion amyloidosis.
Although all amyloid ¢brils share common biochemical and
morphologic features, the generic and speci¢c conformations
remain to be elucidated. Monoclonal antibodies, which bind
to many disease-related amyloid ¢brils but not to non-¢brillar
amyloid proteins, have been generated [23]. In one study it
was found that an anti-AL monoclonal antibody could react
with many other amyloid ¢bril proteins and could inhibit not
only AL amyloidomas but also AA amyloidosis [24]. Re-
cently, the common structure relating to the cell toxicity of
¢brillar amyloid was found in the soluble oligomer of various
amyloid proteins using an oligomer-speci¢c antibody [25,26].
These results support our hypothesis of the existence of a
common structure present in many amyloid ¢brils.
The range of induction of amyloidosis should be sensitive to
the primary structure and other components of amyloid ¢-
brils. Because we do not have a method for further puri¢ca-
tion at this time, it is possible that contaminant molecules
such as ApoE, amyloid P, and other proteoglycans in the
isolated amyloid ¢bril fractions from mouse and human tis-
sues might serve to modify amyloid deposition. In this study
we made amyloid ¢brils using recombinant proteins or syn-
thetic amyloid peptide. We induced AApoAII amyloid depo-
sition successfully using in vitro formed amyloid ¢brils of AK-
synuclein, AGroES, and ALysozyme, and even AL140 amy-
loid peptide. These results con¢rm our hypothesis that the
structure of amyloid ¢brils is essential for the acceleration
of amyloid formation.
In humans, large variations in the occurrence and progres-
sion of amyloidosis have been observed in several popula-
tions. This suggests that endogenous and environmental
agents may play a signi¢cant role in the pathogenesis of amy-
loid-related diseases by a¡ecting the rate of amyloid ¢bril
formation. Many kinds of non-disease-related proteins have
been found that are able to form amyloid ¢brils under certain
conditions. These proteins include myoglobin [14], phospha-
tidyl-inositol-3P-kinase [26], apoC-II [27], the curli subunit in
E. coli [28], and over 100 potential prion proteins in yeast
Saccharomyces cerevisiae [26]. Our results and these ¢ndings
suggest the possibility of cross-acceleration of amyloidosis
among di¡erent forms of amyloid proteins. In our study,
amyloid deposition was induced by injection of relatively large
amounts of amyloid ¢brils (0.1 mg/mouse). Thus a more care-
ful evaluation of the practical importance of this cross-accel-
eration in amyloidosis and further investigation of the mini-
mum amount of amyloid injection needed to induce
deposition and the molecular basis of seeding of heterologous
amyloid ¢bril formation remain.
The induction or acceleration of amyloid disease by amy-
loid ¢bril proteins may require either an elevated level of
amyloid precursor proteins, since in£ammation and hemodial-
ysis elevate plasma AA and L2M protein levels and immuno-
globulin light chains are monoclonally increased in AL amy-
loidosis, or amyloidogenic mutants of precursor proteins.
Almost all hereditary amyloidoses are associated with mutant
amyloid proteins. In this study, heterologous amyloid ¢brils
could not induce amyloidosis in SAMR1 mice which do not
have elevated or amyloidogenic precursor proteins. However,
normal prion protein (PrPc) develops the conformational
change into PrPsc seeded by PrPsc. Thus, general amyloidosis
should be considered a distinct process from the prion dis-
eases.
In conclusion, our results demonstrate the existence of a
common structure in amyloid ¢brils that serves as a seed for
the acceleration of amyloidosis. This feature should contribute
to the understanding of amyloid pathology and may bene¢t
the development of therapeutic agents for amyloid diseases.
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